Virus-like particle

SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19

Retrieved on: 
Tuesday, September 8, 2020
Medical specialties, Vaccines, Medicine, Vaccination, Vaccine, Virology, Virus-like particle, Adar Poonawalla, RTT, COVID-19 vaccine, H5N1 clinical trials

SpyBiotech has signed an exclusive global licensing agreement with SIIPL for the development of a novel virus-like-particle (VLP) vaccine targeting COVID-19.

Key Points: 
  • SpyBiotech has signed an exclusive global licensing agreement with SIIPL for the development of a novel virus-like-particle (VLP) vaccine targeting COVID-19.
  • HBsAg VLPs are a licensed vaccine with excellent safety and immunogenicity data in humans and which are currently manufactured to billions of doses.
  • SpyBiotech has exclusive rights from the University of Oxford to apply, commercialise and sub-license the plug and display technology for vaccine development.
  • Adar Poonawalla, Chief Executive Officer of SIIPL, added: We are very excited about the collaboration with SpyBiotech to work on this novel vaccine for COVID-19.

Predictive Oncology and Dr. Daniel Carter Collaborating to Develop a Potential COVID-19 Vaccine Utilizing Novel Nanoparticle Vaccine Platform, Based on NSP-10

Retrieved on: 
Wednesday, May 6, 2020
Vaccination, Virus-like particle, Branches of biology, Vaccines, Virus, Vaccine, DNA vaccination, Biology

POAI has entered into an agreement with Dr. Carter under which POAI is licensing this technology, subject to certain conditions including additional documentation.

Key Points: 
  • POAI has entered into an agreement with Dr. Carter under which POAI is licensing this technology, subject to certain conditions including additional documentation.
  • NSP-10 is a newly patented self-assembling nanoparticle technology sometimes referred to as virus-like particles or VLP (4).
  • In the case of a DNA vaccine, the DNA instructs the bodys cells to make the Legos in mass which assemble into numerous vaccine particles.
  • Rose and E. Wilson, A Unique Protein Self-Assembling Nanoparticle with Significant Advantages in Vaccine Development and Production,J.

iBio Announces Development of Proprietary COVID-19 Vaccine Candidates

Retrieved on: 
Wednesday, March 18, 2020
Virus-like particle, Vaccine, Contract manufacturing organization, Branches of biology

We are pleased with both the speed of our development activities and the quality of the VLPs our technology is yielding in practice, said Tom Isett, Co-Chairman & CEO of iBio.

Key Points: 
  • We are pleased with both the speed of our development activities and the quality of the VLPs our technology is yielding in practice, said Tom Isett, Co-Chairman & CEO of iBio.
  • I am optimistic about the potential of our COVID-19 vaccine program, said Dr. Sylvain Marcel, iBios VP of Protein Expression Sciences.
  • The Companys subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services via its 130,000 square foot facility in Bryan, Texas.
  • Additionally, iBio is developing proprietary products which include IBIO-100 for the treatment of fibrotic diseases.

Medicago Announces Production of a Viable Vaccine Candidate for COVID-19

Retrieved on: 
Thursday, March 12, 2020
Research, Medical devices, Infectious diseases, Hospitals, Clinical trials, Biotechnology, Health, Pharmaceutical, Science, Vaccination, Vaccine, Virology, Vaccines, Influenza pandemic, Medical specialties, Medicine, Health, Influenza vaccines, Virus-like particle

Production of the VLP is the first step in developing a vaccine for COVID-19, which will now undergo preclinical testing for safety and efficacy.

Key Points: 
  • Production of the VLP is the first step in developing a vaccine for COVID-19, which will now undergo preclinical testing for safety and efficacy.
  • Once this is completed, Medicago expects to discuss with the appropriate Health Agencies to initiate human trials of the vaccine by summer (July/August) 2020.
  • Medicago is a leader in plant-based technology, having previously demonstrated its capability to be a first responder in a flu pandemic.
  • As soon as the genetic sequence of a virus is made available, Medicago can develop a clinical-grade vaccine candidate in only a few weeks.

Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate

Retrieved on: 
Monday, January 13, 2020
Medical specialties, Medicine, RTT, Microbiology, Emergent BioSolutions, Vaccination, Virology, Virus-like particle, Chikungunya, Emergent, Vaccine

GAITHERSBURG, Md., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced that it has received agreement from the European Medicines Agency (EMA) to pursue its proposed development plan for its chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate.

Key Points: 
  • GAITHERSBURG, Md., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced that it has received agreement from the European Medicines Agency (EMA) to pursue its proposed development plan for its chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate.
  • Emergent is encouraged by the concurrence we have received from EMA in paving the path for chikungunya vaccine development based on SNA as the surrogate endpoint, said Abbey Jenkins, senior vice president and vaccines business unit head at Emergent BioSolutions.
  • Emergents CHIKV VLP vaccine candidate is currently being investigated in a Phase 2 parallel-group, randomized, double-blind, dose-finding study of approximately 430 healthy adults at three U.S. sites.
  • The CHIKV VLP vaccine candidate is licensed from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

GeoVax Presenting at Upcoming October European Scientific Conferences

Retrieved on: 
Tuesday, October 15, 2019
Vaccines, Medical specialties, Medicine, Drugs, Modified vaccinia Ankara, Vaccine, GeoVax, Vaccinia, HIV vaccine, Cancer immunotherapy, Immunogenicity, Virus-like particle

ATLANTA, GA, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that it will be represented during presentations at the following upcoming European scientific conferences.

Key Points: 
  • ATLANTA, GA, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that it will be represented during presentations at the following upcoming European scientific conferences.
  • Festival of Biologics / World Immunotherapy Congress, Basel, Switzerland, Oct. 15-17
    Farshad Guirakhoo, PhD, GeoVax Chief Scientific Officer, will deliver an oral presentation entitled,Utilizing a Live Modified Vaccinia Ankara Virus to Deliver Cancer Antigens in Highly Immunogenic Forms of Virus Like Particles.
  • Commenting on these presentations, David Dodd, GeoVax CEO, stated, We are pleased in the continued and increasing recognition of the GeoVax MVA-VLP technology and expertise, ranging from immuno-oncology to various infectious diseases.
  • GeoVaxs HIV vaccine is also part of collaborative efforts to develop an immunotherapy as a functional cure for HIV.

Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate

Retrieved on: 
Thursday, October 10, 2019
Medical specialties, Medicine, RTT, Chikungunya, Microbiology, Virus-like particle, Emergent BioSolutions, VLP, Vaccine

GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the companys chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was granted PRIority MEdicines, or PRIME, designation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) during its September meeting.

Key Points: 
  • GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the companys chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was granted PRIority MEdicines, or PRIME, designation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) during its September meeting.
  • The CHIKV VLP vaccine candidate is being developed for the prevention of disease caused by chikungunya virus infection, an illness that spreads through mosquito bites and for which no vaccine or treatment is available.
  • The CHIKV VLP vaccine candidate is licensed from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
  • The chikungunya virus was found for the first time in the Americas on islands in the Caribbean in 2013.

Icosavax Launches with $51 Million Series A Financing to Advance Computationally Designed VLP Vaccines

Retrieved on: 
Thursday, October 3, 2019
Other Health, University, Pharmaceutical, Education, General Health, Infectious diseases, Science, Biotechnology, Other Science, Research, Health, Vaccination, Drugs, Vaccines, Medicine, Papillomavirus, Cancer vaccines, RTT, Infectious causes of cancer, Cervarix, Gardasil, Virus-like particle, Vaccine

VLPs contain no genetic material, so they are non-infectious and can provide a safer alternative to live-attenuated or inactivated vaccines.

Key Points: 
  • VLPs contain no genetic material, so they are non-infectious and can provide a safer alternative to live-attenuated or inactivated vaccines.
  • Naturally occurring VLPs have delivered successful vaccines, including Gardasil and Cervarix against human papillomavirus (HPV) and Engerix-B and Recombivax HB against Hepatitis B.
  • Ralf developed and brought to licensure more than 25 different vaccines and has published extensively on vaccines and public health.
  • Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs.

GeoVax Issues Shareholder Update Letter

Retrieved on: 
Friday, August 2, 2019
Vaccines, Viruses, Medicine, Medical specialties, Modified vaccinia Ankara, GeoVax, Vaccinia, Vaccine, Virus-like particle, Bavarian Nordic, Vaccines, Viruses, Medicine, Medical specialties, Modified vaccinia Ankara, GeoVax, Vaccinia, Vaccine, Virus-like particle, Bavarian Nordic

ATLANTA, GA, Aug. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines and immunotherapies, today issued an update letter to its shareholders and other interested parties.

Key Points: 
  • ATLANTA, GA, Aug. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines and immunotherapies, today issued an update letter to its shareholders and other interested parties.
  • In the letter, GeoVax President and CEO, David Dodd, addresses the recent erosion of GeoVaxs common stock price and provides an update on each of the Companys development programs, including its shifting focus to immuno-oncology.
  • The letter is posted to the Companys website and can be read in its entirety by visiting www.geovax.com .
  • GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform.

MT-2271 (Mitsubishi Tanabe Pharma) Drug Overview 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 28, 2019
Health, Pharmaceutical, Medical specialties, RTT, Medicine, Infectious diseases, Mitsubishi companies, Vaccination, Virology, Influenza vaccine, Vaccines, Mitsubishi Tanabe Pharma, Vaccine, Virus-like particle

MT-2271 is a plant-based, recombinant virus-like particle (VLP) QIV seasonal influenza vaccine in development by Mitsubishi Tanabe Pharma.

Key Points: 
  • MT-2271 is a plant-based, recombinant virus-like particle (VLP) QIV seasonal influenza vaccine in development by Mitsubishi Tanabe Pharma.
  • Based on Mitsubishi Tanabe Pharma's plan to complete the Phase III study in the elderly in 2019, the company intends to launch the vaccine in the US and EU for adults aged 18-64 years in time for the 2020/21 season (Mitsubishi Tanabe Pharma, 2018).
  • Provided positive results are obtained in the pediatric population, the company could launch the vaccine as early as the 2022/23 season.
  • MT-2271 is a plant-based, recombinant virus-like particle (VLP) QIV seasonal influenza vaccine in development by Mitsubishi Tanabe Pharma.